Medications that mimic GLP-1 (such as semaglutide [Ozempic, Wegovy] and tirzepatide [Mounjaro]) have been shown to support safe, effective weight loss
Key considerations include: Watching for signs of pancreatitis or gallbladder disease Looking at the patients overall health and medical history Changing the dosage or stopping treatment if side effects happen In patients with a history of gallbladder disease or cholecystectomy, the decision to start or keep using GLP-1 receptor agonist therapy should be made on a case-by-case basis
Moments like Date night with your spouse Your childs birthday party Coffee outings with your friends Holidays with the whole family around Without sufficient sleep, you might find that you arent fully present for these moments
As evidence grows, these guidelines must evolve to reflect the latest research, ensuring patients receive the most effective care
Liraglutide-induced pancreatitis: a case report and literature review
However, many patients begin to see improvements in weight and metabolic parameters within the first few weeks to months of starting treatment
